DK0679187T3 - Fremgangsmåde til udvinding af native, oligomere, glycosolerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV - Google Patents

Fremgangsmåde til udvinding af native, oligomere, glycosolerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Info

Publication number
DK0679187T3
DK0679187T3 DK94904568.6T DK94904568T DK0679187T3 DK 0679187 T3 DK0679187 T3 DK 0679187T3 DK 94904568 T DK94904568 T DK 94904568T DK 0679187 T3 DK0679187 T3 DK 0679187T3
Authority
DK
Denmark
Prior art keywords
protein
pct
native
ectodomains
hiv
Prior art date
Application number
DK94904568.6T
Other languages
English (en)
Other versions
DK0679187T4 (da
Inventor
Manfred Schawaller
Original Assignee
Manfred Schawaller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6478309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0679187(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Manfred Schawaller filed Critical Manfred Schawaller
Application granted granted Critical
Publication of DK0679187T3 publication Critical patent/DK0679187T3/da
Publication of DK0679187T4 publication Critical patent/DK0679187T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK94904568T 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV DK0679187T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301017 1993-01-16
PCT/DE1994/000022 WO1994016081A1 (de) 1993-01-16 1994-01-12 Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv

Publications (2)

Publication Number Publication Date
DK0679187T3 true DK0679187T3 (da) 1997-12-08
DK0679187T4 DK0679187T4 (da) 2001-09-17

Family

ID=6478309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94904568T DK0679187T4 (da) 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Country Status (9)

Country Link
US (1) US6140059A (da)
EP (1) EP0679187B2 (da)
JP (1) JP3658690B2 (da)
AT (1) ATE153380T1 (da)
DE (2) DE4400659C2 (da)
DK (1) DK0679187T4 (da)
ES (1) ES2102815T5 (da)
GR (1) GR3023717T3 (da)
WO (1) WO1994016081A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
EP1214333A4 (en) * 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc STABILIZED SOLUBLE GLYCOPROTEINTRIMERE
US7179468B1 (en) 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004101598A2 (en) * 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
WO2010039224A2 (en) * 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
DK2406286T3 (da) 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40-antistoffer og anvendelser deraf
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012135132A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731874A1 (de) * 1987-09-18 1989-03-30 Schering Ag Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
ATE207930T1 (de) † 1990-03-09 2001-11-15 Chiron Corp Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Also Published As

Publication number Publication date
EP0679187B1 (de) 1997-05-21
DE4400659C2 (de) 1995-07-27
WO1994016081A1 (de) 1994-07-21
ATE153380T1 (de) 1997-06-15
DK0679187T4 (da) 2001-09-17
JPH08505769A (ja) 1996-06-25
US6140059A (en) 2000-10-31
EP0679187B2 (de) 2001-07-04
ES2102815T5 (es) 2001-11-16
GR3023717T3 (en) 1997-09-30
ES2102815T3 (es) 1997-08-01
DE4400659A1 (de) 1994-07-21
JP3658690B2 (ja) 2005-06-08
EP0679187A1 (de) 1995-11-02
DE59402827D1 (de) 1997-06-26

Similar Documents

Publication Publication Date Title
DK0679187T3 (da) Fremgangsmåde til udvinding af native, oligomere, glycosolerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
Earl et al. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
DE3751751D1 (de) Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
US6420141B1 (en) Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
WO2003038057A3 (en) Genetic vaccine against human immunodeficiency virus
DK605987D0 (da) Bestemte dna-sekvenser afledt af et papillomavirus-genom, deres anvendelse til in vitro diagnoseformaal og fremstilling af antigeniske praeparater
ES2016426A6 (es) Un procedimiento para detectar la presencia de anticuerpos frente a virus del sida en el suero humano.
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Sattentau et al. Antibody neutralization of HIV-1 and the potential for vaccine design
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
KR950005326A (ko) 재조합 아데노바이러스 백신
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
IL158981A0 (en) Tsg101 as inhibitor of hiv production
DE69021886T2 (de) Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b.
ATE438714T1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
AP2005A (en) Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof.